Skip to main content
ZTS logo

Zoetis Inc. (ZTS) Stock: Price, Forecast & Analyst Target

Zoetis Inc. (ZTS) — MoonshotScore 87/100 (Exceptional band), calculated Nov 18, 2026. Price $85.57 (+2.50%), as of the Nov 18, 2026 trading session; market cap $34.8B. Expected results Feb 11, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$85.57 +$2.09 (+2.50%) Market Cap $34.8B

Zoetis Inc. · ZTS · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

Research dated 2026-09-12: Zoetis develops and sells animal medicines, vaccines, diagnostics and related technologies to veterinarians, livestock producers and retail channels across companion-animal and livestock markets. The case depends on whether pricing support can protect demand and market share without weakening the strong profitability and cash generation that distinguish the business.

Price as of Nov 18, 2026

Key Statistics

87 of 100

MoonshotScore v2 · Zoetis (ZTS)

Exceptional
Business Quality Elite (96)
Financial Safety Okay (48)
Valuation Full (58)
Growth Durability Growing (79)
Momentum Rising (71)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Rising.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 11, 2027
  • Altman Z 4.79 · Piotroski F 6

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ZTS (57 recorded, newest six shown)
RecordedScoreBand
86Exceptional
87Exceptional
87Exceptional
87Exceptional
87Exceptional
87Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$85.57
Change on the day+2.50%
52-week range$68.77–$132.49
Market capitalisation$34.8B—
Price / earnings (trailing)14.17
Shares traded on the day4.66M
Beta (volatility vs the S&P 500)0.68

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $70, high $146, latest $86. $146 $70 high $146 Oct 17, 2025 Nov 18, 2026 · $86 $144Oct 17, 2025$144Oct 31, 2025$121Nov 14, 2025$128Nov 28, 2025$119Dec 12, 2025$126Dec 26, 2025$127Jan 9, 2026$124Jan 23, 2026$127Feb 6, 2026$129Feb 20, 2026$121Mar 6, 2026$116Mar 20, 2026$118Apr 2, 2026$122Apr 17, 2026$114May 1, 2026$74May 15, 2026$78May 29, 2026$80Jun 12, 2026$76Jun 26, 2026$76Jul 10, 2026$75Jul 24, 2026$73Aug 7, 2026$78Aug 21, 2026$76Sep 4, 2026$71Sep 18, 2026$70Oct 2, 2026$79Oct 16, 2026$80Oct 30, 2026$84Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Zoetis (ZTS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Moderate
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Weak
Debt/Equity Negative
ROE Strong
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Zoetis (ZTS), and what does it report?

Short answer · as of

Zoetis is an animal-health company, not a conventional human-drug manufacturer. Demand comes from disease prevention, parasite control, pain and allergy treatment, oncology, reproductive care, diagnostic testing and livestock productivity across dogs, cats, horses, cattle, swine, poultry, fish and sheep.

Reported revenue therefore reflects a broad mix of veterinary pharmaceuticals, vaccines, diagnostics, laboratory services and related animal-health offerings sold directly and through distributors. Species categories help describe exposure, while the consolidated statements capture the economics of the portfolio as a whole.

2 · Latest results

What do the latest results show for Zoetis (ZTS)?

Latest-period revenue edged above the comparable result, while operating profit and net income declined. Revenue also came in below the prevailing estimate, although reported earnings exceeded the estimate, leaving a mixed result: demand held roughly steady, but the profit conversion was weaker.

Management says it is accelerating gross-to-net pricing investments to maintain or increase volume and protect or gain share. That is the stated mechanism to watch, rather than an established explanation for the entire earnings movement: commercial concessions may support demand, but their value depends on whether volume and share respond without sustained margin erosion.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$2.42B$721M$1.63 (diluted)
Q4 FY2025$2.39B$603M$1.37 (diluted)
Q1 FY2026$2.26B$601M$1.42 (diluted)
Q2 FY2026$2.47B$691M$1.65 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Zoetis (ZTS)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Zoetis combines high gross and operating margins with recurring positive operating cash flow and continued capital investment. Annual revenue, net income and research spending have also advanced across the reported history, supporting the picture of a profitable franchise that continues to fund product development.

Leverage is the main financial constraint. Debt materially exceeds cash and short-term investments, and the company is in a net-debt position despite healthy liquidity ratios and limited net cash movement across the reported window. A prolonged trade-off between commercial pricing support and profitability would matter more under that capital structure than it would for a cash-rich peer.

4 · What to check next?

What should you watch next at Zoetis (ZTS)?

Short answer · as of

The next earnings report is expected on Feb 11, 2027.

Watch whether the next earnings release shows revenue returning above expectations while operating profit stabilizes relative to sales. That combination would indicate that commercial pricing support is helping defend demand without allowing concessions to consume the portfolio’s margin strength.

Cash conversion deserves equal attention: operating cash flow should continue to cover capital spending while liquidity remains resilient against the debt load. Research spending should also be tracked alongside annual growth, because Zoetis must replenish and extend a portfolio spanning therapeutics, vaccines and diagnostics rather than rely on a narrow product set.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Zoetis compare with its peers?

Short answer

Zoetis's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Zoetis differs from a typical specialty-drug company because its customers treat animals rather than people, and its commercial reach spans veterinary clinics, livestock operations, distributors and retail channels. Pharmaceuticals and vaccines sit beside point-of-care instruments, reference laboratories, genetic testing, biodevices and precision-animal-health tools, creating several routes into the same care ecosystem.

The breadth cuts across companion animals and production animals, so demand is tied to pet care as well as herd and flock health. That diversification is genuinely distinctive, but it also makes species demand, channel conditions and commercial pricing actions more informative than a simple comparison with human pharmaceutical manufacturers.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Lantheus Holdings, Inc. (LNTH) Same industry, near in market value$102.00 Nov 18, 2026$6.67B96 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Named competitor$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Elevance Health Inc. (ELV) Named competitor$400.84 Nov 18, 2026$86.6B88 5-pillar Nov 18, 2026
Zoetis (ZTS) — this page$85.57$34.8B87
Cencora, Inc. (COR) Named competitor$348.28 Nov 18, 2026$66.5B86 5-pillar Nov 18, 2026
Cigna Corporation (CI) Named competitor$285.38 Nov 18, 2026$75.2B78 5-pillar Nov 18, 2026
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.98 Nov 18, 2026$12.5B77 5-pillar Nov 18, 2026
Haleon plc (HLN) Same industry, near in market value$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.96 Nov 18, 2026$6.02B74 5-pillar Nov 18, 2026
Takeda Pharmaceutical Company Limited (TAK) Named competitor$21.27 Nov 18, 2026$68.0B73 5-pillar Nov 18, 2026
HUTCHMED (China) Limited (HCM) Same industry, near in market value$13.99 Nov 18, 2026$2.43B70 5-pillar Nov 18, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Same industry, near in market value$21.88 Nov 18, 2026$7.62B66 5-pillar Nov 18, 2026
Teva Pharmaceutical Industries Limited (TEVA) Same industry, near in market value$42.23 Nov 18, 2026$49.3B57 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$74.00 – $95.00
Consensus target
$84.75
Median target
$84.00

Consensus record · Captured .

Measured against a quoted price of $85.57 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 30, 2026

Transactions
26
Identified insiders
13
Purchases
0
Sales
0
Other transactions
26

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ZTS in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.14%$33.26MAdded +254.9% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Zoetis (ZTS)?

Read these with our analysis →

Zoetis Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Zoetis not simply a human drug company for animals?

Zoetis sells more than medicines: its portfolio includes vaccines, point-of-care diagnostics, reference laboratory services, genetic testing, biodevices and precision-animal-health offerings. Revenue therefore depends on veterinary care and livestock health workflows, not merely prescriptions.

How could Zoetis pricing investments affect animal-health demand?

Management is using gross-to-net pricing investments to support volume and market share. The useful test is whether revenue and share respond while operating profit remains resilient, since concessions that preserve demand but erode profitability would weaken the economics.

Does Zoetis generate cash after funding its animal-health operations?

Operating cash flow has remained positive and above capital spending throughout the reported quarterly series. That supports internal funding capacity, although debt remains far above cash and short-term investments.

Why do companion animals and livestock matter differently to Zoetis?

Companion-animal demand runs through veterinary treatment, diagnostics and chronic-care products, while livestock demand includes disease prevention, anti-infectives, parasiticides, medicated feed additives and productivity tools. Exposure across these animal groups broadens the revenue base but leaves the portfolio sensitive to different care settings and purchasing channels.

What is the ZTS stock price today?

The last price recorded for Zoetis Inc. (ZTS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ZTS price target?

The analyst consensus price target for Zoetis Inc. (ZTS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is Zoetis (ZTS), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Zoetis (ZTS)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for Zoetis (ZTS)?: Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Distress and quality screens
  • 4. What should you watch next at Zoetis (ZTS)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Annual revenue and net result (USD millions); Business description
  • 5. How does Zoetis compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Why is Zoetis not simply a human drug company for animals?: Business description; Sector / industry (provider taxonomy)
  • FAQ: How could Zoetis pricing investments affect animal-health demand?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set
  • FAQ: Does Zoetis generate cash after funding its animal-health operations?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash against market value
  • FAQ: Why do companion animals and livestock matter differently to Zoetis?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ZTS

Funds in our ETF coverage that list ZTS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Scharf ETF (KAT)3.91%